Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Mesotherapy Treatments for Androgenetic Alopecia: Evidence, Options, and Practical Pearls

Description

The talk reviews mesotherapy for androgenetic alopecia, emphasizing that many patients prefer local treatments to avoid systemic side effects, hormonal exposure, and fertility concerns. Mesotherapy can deliver bioactive agents intradermally with better local bioavailability, but evidence is limited and protocols are not well standardized. Among available agents, dutasteride has the strongest evidence and is considered the most studied and effective option for both sexes, especially for patients who want to avoid systemic therapy; suggested regimens include small-volume injections every three months, with contraception recommended for women. However, clinicians should avoid problematic solvents such as ethanol and propylene glycol, since these can contribute to adverse effects including paradoxical alopecia, irritation, and contact dermatitis. Other options discussed include bicalutamide, minoxidil, multicomponent hair boosters, growth factors, exosomes, and salmon-derived products, though these generally have less evidence. The speaker stresses that successful treatment depends not only on anti-androgens but also on maintaining a healthy scalp microenvironment, and that exosomes may be useful when delivered by microneedling because injectable use is not legally established. Practical advice includes using simple low-cost delivery methods, small injection volumes to avoid pressure alopecia, and being alert to side effects such as pain, headache, pruritus, edema, and rare hypersensitivity reactions. Overall, dutasteride mesotherapy is presented as the best-supported approach, exosomes with microneedling as a hormone-free alternative, and systemic therapy as the better choice for advanced disease.

View more

Conclusions

Intralesional and mesotherapy approaches can be useful alternatives for androgenetic alopecia, especially for patients who want to avoid systemic or hormonal treatment.
Among injectable options, dutasteride appears to have the strongest evidence and is presented as the most studied and effective mesotherapy agent.
Treatment response is influenced by patient factors such as metabolic syndrome, so androgenetic alopecia should not be managed as an anti-androgen problem alone.
Bicalutamide and minoxidil may help selected patients, but their evidence and outcomes are more variable than dutasteride.
Non-hormonal options such as vitamins, peptides, growth factors, and exosomes are promising, but they have weaker evidence and less standardization.
A healthy scalp microenvironment is emphasized as necessary for durable hair-growth results beyond the choice of drug alone.
Technique matters: small injection volumes, appropriate depth, and careful protocols can improve outcomes and reduce complications like pressure alopecia.
Exosomes with microneedling are presented as a potential hormone-free option, but their use is limited by lack of standardization and regulatory approval.
Adverse effects are often related to the vehicle or technique, including ethanol-related alopecia, edema, pain, dermatitis, and hypersensitivity reactions.
For advanced androgenetic alopecia, the presentation concludes that systemic treatment may still be necessary rather than relying only on local injectable therapies.

Beer et al. Injectable Therapy for Androgenetic Alopecia. Dermatologic Surgery. January 2026.
Gupta et al.
Aledani et al.
J. Clin. Med. 2026, 15, 1836. DOI: https://doi.org/10.3390/jcm15051836#10.3390/jcm15051836